Seeking Alpha

FDA Ad Com Friday for Aimmune's AR101 for peanut allergy; shares up 8%

|About: Aimmune Therapeutics, ... (AIMT)|By:, SA News Editor

The FDA's Allergenic Products Advisory Committee will meet on Friday, September 13, to review and discuss Aimmune Therapeutics' (NASDAQ:AIMT) marketing application for AR101, branded as Palforzia, to reduce the incidence and severity of allergic reactions to peanut in young people aged 4 - 17 who have a confirmed diagnosis of peanut allergy.

Shares are up 8% premarket on light volume as investors perceive no significant hurdles that might trip up a positive vote.

FDA briefing doc

Company briefing doc

Subscribe for full text news in your inbox